Page 91 - Immunization Practices News Today

The US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines from Pfizer Inc (NYSE: PFE) and GSK plc (NYSE:

ACIP stops short of full-throated endorsement, recommends a talk with medical provider first

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots. In two separate…

A key committee backed a policy saying adults 65 and older "may receive" the shots, rather than one saying the injections "are recommended."

PHILADELPHIA--(BUSINESS WIRE)--Jun 21, 2023--

Reuters Intel's Manufacturing Overhaul: Aims for Second Largest Foundry Spot with Projected Revenue Over $20B Intel Corp (NASDAQ: INTC) has had an eventful week so far, enlightening investors with significant turnaround updates. On Wednesday, the company voiced plans to restructure its manufacturing business, likely to work like a separate unit and begin to generate a margin. The chipmaker neither disclosed any timeline for the restructuring nor named a new external customer for the busines...

The vote marks the penultimate step before shots can become available by fall, with only the CDC director's expected formal endorsement needed.

*Launch is planned in the US before the 2023 RSV season *Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time1 *RSV causes approximately 177,000 hospitalisations and 14,000 deaths i...

CDC advisory panel voted to recommend that adults 60 and older may receive a single dose of RSV vaccine, with shared-decision making with a healthcare provider.

The Advisory Committee on Immunization Practices stopped short of recommending the vaccines for everyone age 65 and above.